We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

127 hedge funds and large institutions have $957M invested in Aclaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

12% more capital invested

Capital invested by funds: $851M → $957M (+$106M)

10% more funds holding

Funds holding: 115 → 127 (+12)

1% more call options, than puts

Call options by funds: $362K | Put options by funds: $357K

0.32% more ownership

Funds ownership: 95.03% → 95.35% (+0.32%)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

Holders
127
Holders Change
+12
Holders Change %
+10.43%
% of All Funds
2.19%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
19
Increased
48
Reduced
26
Closed
6
Calls
$362K
Puts
$357K
Net Calls
+$5K
Net Calls Change
-$250K

Top Buyers

1
O
OrbiMed
New York
+$6.82M
2
Walleye Capital
Walleye Capital
New York
+$4.25M
3
Charles Schwab
Charles Schwab
California
+$3.91M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.6M
5
BlackRock
BlackRock
New York
+$2.21M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$22.8M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.28M
3
LCM
Laurion Capital Management
New York
-$2.13M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.55M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
51
UBS AM
Illinois
$1.36M +$6.92K +439 +0.5%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$1.31M +$181K +11,493 +16%
Ameriprise
53
Ameriprise
Minnesota
$1.15M -$32.2K -2,047 -3%
Bank of America
54
Bank of America
North Carolina
$1.13M -$392K -24,880 -26%
Allspring Global Investments
55
Allspring Global Investments
North Carolina
$1.04M +$1.04M +66,136 New
California State Teachers Retirement System (CalSTRS)
56
California State Teachers Retirement System (CalSTRS)
California
$1.03M +$57K +3,618 +6%
HighTower Advisors
57
HighTower Advisors
Illinois
$919K -$27.4K -1,739 -3%
CS
58
Candriam SCA
Luxembourg
$886K +$887K +56,279 New
TRSOTSOK
59
Teachers Retirement System of the State of Kentucky
Kentucky
$850K +$851K +54,011 New
Dimensional Fund Advisors
60
Dimensional Fund Advisors
Texas
$756K +$756K +48,017 New
T. Rowe Price Associates
61
T. Rowe Price Associates
Maryland
$742K +$143K +9,077 +24%
State of Wisconsin Investment Board
62
State of Wisconsin Investment Board
Wisconsin
$737K -$25.8K -1,636 -3%
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
$737K +$125K +7,953 +20%
AllianceBernstein
64
AllianceBernstein
Tennessee
$726K – – –
RCM
65
Requisite Capital Management
Texas
$708K – – –
CS
66
Credit Suisse
Switzerland
$652K +$70.1K +4,450 +12%
MIM
67
MetLife Investment Management
New Jersey
$492K – – –
AIG
68
American International Group
New York
$483K +$42K +2,669 +10%
Invesco
69
Invesco
Georgia
$456K +$66.4K +4,216 +17%
Connor, Clark & Lunn Investment Management (CC&L)
70
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$423K +$423K +26,854 New
Mirae Asset Global Investments
71
Mirae Asset Global Investments
South Korea
$420K +$165K +10,467 +64%
Manulife (Manufacturers Life Insurance)
72
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$368K -$7.06K -448 -2%
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
$355K +$355K +22,536 New
Allianz Asset Management
74
Allianz Asset Management
Germany
$343K -$1.23M -78,030 -78%
BNP Paribas Financial Markets
75
BNP Paribas Financial Markets
France
$332K +$122K +7,717 +58%
1 2
3
4 5

ACRS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2022, worth a combined $957M — up 12% from $851M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ACRS positions and 6 closed out — a net gain of 13 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was OrbiMed, adding an estimated $6.82M. The largest seller was Wellington Management Group, cutting an estimated $22.8M.

  • 127 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $957M of Aclaris Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
  • 19 funds opened new Aclaris Therapeutics positions in Q3 2022 and 6 closed out, a net change of +13 holders.
  • The largest Aclaris Therapeutics buyer in Q3 2022 was OrbiMed, an estimated $6.82M added.
  • The largest Aclaris Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $22.8M sold.

Based on aggregated 13F filings for Q3 2022.